Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020112773 - TARGETING INTRAEPITHELIAL LYMPHOCYTES FOR TREATMENT OF METABOLIC SYNDROME

Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

[ EN ]

WHAT IS CLAIMED IS:

1. A method of reducing risk of developing metabolic syndrome or a disease

associated with metabolic syndrome in a subject with a family history of metabolic syndrome or a disease associated with metabolic syndrome , elevated blood pressure, dysglycemia, or abdominal obesity, the method comprising administering a therapeutically effective amount of a b7 integrin inhibitor to the subject in need thereof.

2. The method of claim 1, wherein the metabolic syndrome or the disease associated with metabolic syndrome is atherosclerosis.

3. The method of claim 1, wherein the b7 integrin inhibitor is natalizumab or

vedolizumab or etrolizumab.

4. The method of claim 1, wherein the therapeutically effective amount of the b7 integrin inhibitor is sufficient to inhibit intraepithelial lymphocyte recruitment to small intestine.

5. The method of claim 4, wherein the b7 integrin inhibitor is delivered directly to the small intestine of the subject, e.g., intraperitoneally, subcutaneously, or by administering the b7 integrin inhibitor in an oral form that remains intact in the stomach but releases the inhibitor once in the small intestine.

6. The method of claim 1, wherein the subject has not been diagnosed with a

metabolic syndrome or the disease associated with metabolic syndrome.

7. The method of claim 1, wherein the subject does not have a chronic inflammatory bowel disease.

8. The method of claim 7, wherein the chronic inflammatory bowel disease is

irritable bowel syndrome, Crohn’s disease, or ulcerative colitis.

9. A method of treating a subject who has been diagnosed with metabolic syndrome or a disease associated with metabolic syndrome , the method comprising administering a therapeutically effective amount of a b7 integrin inhibitor to the subject in need thereof.

10. The method of claim 9, wherein the metabolic syndrome or the disease associated with metabolic syndrome is atherosclerosis.

11. The method of claim 9, wherein the b7 integrin inhibitor is natalizumab or

vedolizumab or etrolizumab.

12. The method of claim 9, wherein the therapeutically effective amount of the b7 integrin inhibitor is sufficient to inhibit intraepithelial lymphocyte recruitment to small intestine.

13. The method of claim 12, wherein the b7 integrin inhibitor is delivered directly to the small intestine of the subject, e.g., intraperitoneally, subcutaneously, or by administering the b7 integrin inhibitor in an oral form that remains intact in the stomach but releases the inhibitor once in the small intestine.

14. The method of claim 9, wherein the subject does not have a chronic inflammatory bowel disease.

15. The method of claim 14, wherein the chronic inflammatory bowel disease is irritable bowel syndrome, Crohn's disease, or ulcerative colitis.

16. A method of reducing risk of developing metabolic syndrome or a disease

associated with metabolic syndrome in a subject with family history of metabolic syndrome or a disease associated with metabolic syndrome, elevated blood pressure, dysglycemia, or abdominal obesity, the method comprising

administering a therapeutically effective amount of a CCR9 inhibitor or a GLP-1 agonist to the subject in need thereof.

17. The method of claim 16, wherein the metabolic syndrome or a disease associated with metabolic syndrome is atherosclerosis.

18. The method of claim 16, wherein the CCR9 inhibitor is CCX025 or CCX282.

19. The method of claim 16, wherein the subject has not been diagnosed with a metabolic syndrome or a disease associated with metabolic syndrome.

20. The method of claim 16, wherein the subject does not have a chronic

inflammatory bowel disease.

21. The method of claim 19, wherein the chronic inflammatory bowel disease is irritable bowel syndrome, Crohn's disease, or ulcerative colitis.